Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Blood (2022) 139 (12): 1785–1793.

https://doi.org/10.1182/blood.2021012328

Published: 2022

Includes: Supplemental data

Journal Articles

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Carmelo Rizzari, Anja Moericke, MD, Valentino Conter, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Daniela Silvestri, Georg Mann, MD, Felix Niggli, MD, Luciano Dalla-Pozza, MBBS FRACP, Jan Stary, Prof., MD PhD, Sarah Elitzur, MD, Gunnar Cario, MD, Franco Locatelli, MD, Joachim Boos, MD, Massimo Zucchetti, PharmD, Andrea Biondi, MD, Martin Schrappe, MD PhD

Blood (2019) 134 (Supplement_1): 2589.

https://doi.org/10.1182/blood-2019-123448

Published: 2019

Journal Articles

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

Blood (2019) 134 (Supplement_1): 1351.

https://doi.org/10.1182/blood-2019-126523

Published: 2019

Journal Articles

A Comprehensive FISH- and Array-Based Diagnostic Screeningstrategy for the Assessment of Clinically Relevant Genetic Parameters: A Prospective Analysis of 205 Childhood ALL Cases

Oskar A. Haas, MD, Karin Nebral, PhD, Sabrina Haslinger, BSc, Andrea Inthal, PhD, Margit König, Sabine Strehl, PhD, Renate Panzer-Grümayer, MD, Andishe Attarbaschi, MD, Georg Mann, MD

Blood (2018) 132 (Supplement 1): 4082.

https://doi.org/10.1182/blood-2018-99-115761

Published: 2018

Journal Articles

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

Blood (2017) 130 (19): 2146–2149.

https://doi.org/10.1182/blood-2017-05-782086

Published: 2017

Includes: Supplemental data

Journal Articles

The Combination of MRD and Copy Number Alterations (CNAs) Defines an Ultra-High Risk Group of Children with Primary T-Lymphoblastic Leukemia (T-ALL)

Joachim B. Kunz, MD, Julia Seemann, Martin Zimmermann, PhD, Paulina Richter-Pechanska, Obul Reddy Bandapalli, PhD, Elena Orlova, Gunnar Cario, Martin Stanulla, MD, Martin Schrappe, MD PhD, Marketa Zaliova, Jan Trka, MD PhD, Renate Panzer-Grümayer, MD, Georg Mann, MD, Martina U. Muckenthaler, PhD, Jan O. Korbel, PhD, Andreas E Kulozik, MD PhD

Blood (2016) 128 (22): 2911.

https://doi.org/10.1182/blood.V128.22.2911.2911

Published: 2016

Journal Articles

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R. Bartram, PhD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, Rita Beier, MD, Gunnar Cario, Franco Locatelli, MD, Giuseppe Basso, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter

Blood (2016) 128 (22): 4.

https://doi.org/10.1182/blood.V128.22.4.4

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia

Maria Grazia Valsecchi, PhD, Meenakshi Devidas, PhD, Ausiliatrice Lucenti, PhD, Martin Schrappe, MD, Giovanni Cazzaniga, PhD, Anja Moricke, MD, Claus R. Bartram, PhD, Georg Mann, MD, William L. Carroll, MD, Eric Larsen, MD, Naomi Winick, MD, Giuseppe Basso, MD, Valentino Conter, Martin Zimmermann, PhD, Stefan Sushu, Andrea Biondi, MD, Stephen Hunger, MD, Stefania Galimberti, PhD

Blood (2016) 128 (22): 759.

https://doi.org/10.1182/blood.V128.22.759.759

Published: 2016

Journal Articles

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Blood (2016) 127 (17): 2101–2112.

https://doi.org/10.1182/blood-2015-09-670729

Published: 2016

Includes: Supplemental data

Journal Articles

Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report

Wilhelm Woessmann, MD, Martin Zimmermann, Birgit Burkhardt, Andrea Meinhardt, MD, Christine Rosenbusch, MD, Vera Vaillant, MD, Ilske Oschlies, Wolfram Klapper, MD, Felix Niggli, MD, Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, Alfred Reiter, MD

Blood (2014) 124 (21): 1738.

https://doi.org/10.1182/blood.V124.21.1738.1738

Published: 2014

Journal Articles

Invasive Fungal Infections in Pediatric Acute Lymphoblastic Leukemia: Incidence, Characterization, Outcome and Risk Analysis of Study ALL-BFM 2000

Georg Mann, MD, Andishe Attarbaschi, MD PhD, Martin Schrappe, MD, Anja Möricke, Kirsten Bleckmann, MD, Julia Alten, MD, Thomas Lehrnbecher, MD, Martin Zimmermann, PhD, Felix Niggli, MD

Blood (2014) 124 (21): 3658.

https://doi.org/10.1182/blood.V124.21.3658.3658

Published: 2014

Journal Articles

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

Blood (2014) 123 (1): 70–77.

https://doi.org/10.1182/blood-2013-06-509463

Published: 2014

Includes: Supplemental data

Journal Articles

Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2 –harboring clones as main relapse-driving force in childhood ALL

Maria Morak, Andishe Attarbaschi, Susanna Fischer, Christine Nassimbeni, Reinhard Grausenburger, Stephan Bastelberger, Stefanie Krentz, Gunnar Cario, David Kasper, Klaus Schmitt, Lisa J. Russell, Ulrike Pötschger, Martin Stanulla, Conny Eckert, Georg Mann, Oskar A. Haas, Renate Panzer-Grümayer

Blood (2012) 120 (26): 5134–5142.

https://doi.org/10.1182/blood-2012-07-443218

Published: 2012

Includes: Supplemental data

Journal Articles

Outcome of Treatment for Relapsed Acute Lymphoblastic Leukemia in Children with Down Syndrome

Franziska Meyr, MD, Fabian Baumann, MD, Gabriele Escherich, MD, Georg Mann, MD, Thomas Klingebiel, MD, Andreas E Kulozik, MD, PhD, Claudia Rossig, MD, Martin Schrappe, Guenter Henze, MD, Arend von Stackelberg, MD, Johann K. Hitzler, MD

Blood (2012) 120 (21): 669.

https://doi.org/10.1182/blood.V120.21.669.669

Published: 2012

Journal Articles

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Jan Zuna, MD, PhD, Mari Arens, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Anja Möricke, MD, Claus R Bartram, MD, Ruth Joas, Eva Fronkova, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Zimmermann, PhD, Jan Trka, MD, PhD, Jan Stary, M.D., Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, André Schrauder, MD

Blood (2011) 118 (21): 756.

https://doi.org/10.1182/blood.V118.21.756.756

Published: 2011

Journal Articles

Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,

Blood (2011) 118 (21): 3579.

https://doi.org/10.1182/blood.V118.21.3579.3579

Published: 2011

Journal Articles

Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002

Arend von Stackelberg, MD, Junko Yamanaka, MD, Gabriele Escherich, MD, Cornelia Eckert, PhD, Richard Ratei, MD, Johann K. Hitzler, MD, Georg Mann, MD, Lucie Sramkova, MD, Jean-Pierre Bourquin, MD, PhD, Martin Schrappe, MD, Günter Henze, MD

Blood (2011) 118 (21): 871.

https://doi.org/10.1182/blood.V118.21.871.871

Published: 2011

Journal Articles

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Anja Möricke, MD, André Schrauder, MD, Martin Zimmermann, PhD, Georg Mann, MD, Andishe Attarbaschi, MD, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Martin Stanulla, MD, MSc, Gunnar Cario, MD, Alfred Reiter, MD, Felix Niggli, MD, Claus R Bartram, MD, Martin Schrappe, MD

Blood (2011) 118 (21): 1504.

https://doi.org/10.1182/blood.V118.21.1504.1504

Published: 2011

Journal Articles

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma

Andishe Attarbaschi, Georg Mann, Angelo Rosolen, Denise Williams, Anne Uyttebroeck, Ildiko Marky, Laurence Lamant, Keizo Horibe, Grazyna Wrobel, Auke Beishuizen, Wilhelm Wössmann, Alfred Reiter, Audrey Mauguen, Marie-Cecile Le Deley, Laurence Brugières, for the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) ALCL99 Trial

Blood (2011) 117 (21): 5616–5619.

https://doi.org/10.1182/blood-2010-12-324012

Published: 2011

NARROW

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

Incidence of Hypersensitivity Reactions (HSR) Reactions (HSR) to Peg-Asparaginase (PEG-ASP) in 6136 Patients Treated in the AIEOP-BFM ALL 2009 Study Protocol

Poor Prognosis in Children with ABL -Class Fusion Positive B-Cell Acute Lymphoblastic Leukemia Treated According to AIEOP-BFM Protocols

A Comprehensive FISH- and Array-Based Diagnostic Screeningstrategy for the Assessment of Clinically Relevant Genetic Parameters: A Prospective Analysis of 205 Childhood ALL Cases

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL

The Combination of MRD and Copy Number Alterations (CNAs) Defines an Ultra-High Risk Group of Children with Primary T-Lymphoblastic Leukemia (T-ALL)

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Relapsed or Refractory Burkitt Lymphoma in Children and Adolescents after BFM-Type First-Line Therapy - a BFM Group Report

Invasive Fungal Infections in Pediatric Acute Lymphoblastic Leukemia: Incidence, Characterization, Outcome and Risk Analysis of Study ALL-BFM 2000

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group

Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2 –harboring clones as main relapse-driving force in childhood ALL

Outcome of Treatment for Relapsed Acute Lymphoblastic Leukemia in Children with Down Syndrome

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group,

Conventional Reinduction/Consolidation-Type Therapy Versus Short Course High Intensity Combination Chemotherapy As Post-Induction Treatment for Children with Relapsed Acute Lymphoblastic Leukemia. Early Results of Study ALL-REZ BFM 2002

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only